Summary

The PCR technologies market is projected to reach USD 21.89 Billion by 2030 from USD 14.61 in 2024, growing at a CAGR of 7.0% during the forecast period. The market is growing due to numerous factors.Increasing cases of infectious diseases, and regular advancements in PCR technologies drives this market. Rising expenditure in research and development and increase in application of biomarker profiling to detect diseases are other factors. Additionally, the market growth is affected by inclusion of PCR technology with artificial intelligence.

“qPCR to account for largest market share in 2023.”
A variant of the Polymerase Chain Reaction (PCR) called quantitative PCR (qPCR), sometimes referred to as real-time PCR, enables the simultaneous amplification and quantification of a particular DNA or RNA sequence. qPCR tracks the reaction in real time as it develops and provides quantitative information on the amount of target nucleic acid, in contrast to traditional PCR, which only identifies the presence of genetic material after the reaction is finished. The market is driven by the rising demand for qPCR instruments, the increasing prevalence of illnesses, and technical advances. Moreover, qPCR is a very specific and sensitive method for identifying and measuring nucleic acids, which makes it necessary for the diagnosis of infectious disorders.

“Diagnostic Laboratories to hold largest share in the market.”
Various significant factors are propelling the growth of hospitals and diagnostic centers in the microfluidics industry. One important factor is the rising requirement for point-of-care diagnostics, as they provides quick, on-site testing that improves patient outcomes. Moreover, the requirement for efficacious diagnostics in clinical settings has risen due to the increase in infectious diseases like COVID-19. These equipment decrease cost, expedites testing methods, and improve precision and accuracy of diagnosis. Diagnostic labs require PCR identify and diagnose a variety of illnesses. These labs use PCR extensively because of its precision, sensitivity, and speed in diagnosing genetic abnormalities, and infectious diseases.

"North America to register largest share in 2023."
The largest share was hold by North America in 2023. North America comprise US and Canada.
The growth is supported by increase in drug development associated with genomics. Apart from that, government led initiatives and increase in funding and grants supports growth. The region also has strong presence of prominent players who support the growth of this market by carrying out strategic partnerships, collaborations, expansion and acquisitions. Wide application of PCR methods in hospitals and diagnostic labs of this region is also increasing the demand for microfluidics in North America.
A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–35%, Tier 2–45%, and Tier 3– 20%
• By Designation: C-level-- 35%, Director-level–25%, and Others–40%
• By Region: North America–40%, Europe-30%, Asia Pacific–20%, Latin America- 5%, Middle East and Africa- 5%

Prominent players in the PCR technologies market include F. Hoffman-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), QIAGEN (Germany), Sansure Biotech Inc. (China) Becton, Dickinson and Company (US) and Analytik Jena AG (Germany), Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), Standard Biotools (US), Danaher Corporation (US), Abbott Laboratories (US), Merck KGaA (Germany), Illumina, Inc. (US), Bioneer Corporation (South Korea), PerkinElmer Inc. (US), Hologic Inc. (US),.

Research Coverage
The report comprise segmentation that includes end users, products, applications, and geographic regions. It also discusses the key drivers, restraints, opportunities, and challenges affecting the growth of the PCR technologies market. The research offers stakeholders an assessment of market potential and challenges, with a focus on key players and competitive landscapes. Additionally, micromarkets are assessed according to their overall to the microfluidics sector, growth patterns, and potential. The analysis estimates increase in market segment revenues, focusing on five regions.
Key Benefits of Buying the Report:
This research aids new and existing players in the PCR technologies market to assess the sustainability of their investments by offering detailed information. It offers a dataset to assist in making key decisions. The main advantage of this report includes risk evaluation and offering direction for investment decisions. Market segmentation as per the end-users and geographical areas is offered in the study, that provides analysis and insights. It also provides trends, obstacles, opportunities, and drivers, giving stakeholders the information they need to make strategic decisions.

The report provides the insights on the following pointers:

Analysis of the key drivers, restraints, opportunities, and challenges impacting the PCR technologies market growth: advanced technology and rise in prevalence of infectious diseases ; premium price of devices and strict regulations ; rise in number of diagnostic centers/labs.

Product Development/Innovation: Overview of technologies, research & development ventures and launch of innovative product & service for the microfluidics industry.
Market Development: Details related to profitable markets: this research discussees the PCR technologies business in numerous regions.

Market Diversification: Detailed understanding of advanced products, unexplored areas, latest developments, and investment in the market.

Competitive Assessment: Detailed analysis of market share, services and products offered and key strategies adopted by prominent players such as Danaher Corporation (US), Agilent Technologies, Inc. (US), biomerieux (France), Thermo Fisher Scientific Inc. (US) and Abbott laboratories (US).

ページTOPに戻る

Table of Contents

1 INTRODUCTION 27
1.1 STUDY OBJECTIVES 27
1.2 MARKET DEFINITION 27
1.3 STUDY SCOPE 28
1.3.1 SEGMENTS CONSIDERED 28
1.3.2 INCLUSIONS & EXCLUSIONS 28
1.3.3 YEARS CONSIDERED 29
1.3.4 CURRENCY CONSIDERED 29
1.4 STAKEHOLDERS 29
1.5 SUMMARY OF CHANGES 30
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH DATA 31
2.2 RESEARCH DESIGN 32
2.2.1 SECONDARY RESEARCH 32
2.2.1.1 Key secondary sources 32
2.2.1.2 Key objectives of secondary research 33
2.2.1.3 Key data from secondary sources 34
2.2.2 PRIMARY RESEARCH 34
2.2.2.1 Key primary sources 35
2.2.2.2 Key objectives of primary research 35
2.2.2.3 Key industry insights 36
2.2.2.4 Breakdown of primaries 36
2.3 MARKET SIZE ESTIMATION 37
2.3.1 BOTTOM-UP APPROACH 38
2.3.1.1 Company revenue estimation approach 38
2.3.1.2 Customer-based market estimation 39
2.3.1.3 Top-down approach 40
2.3.1.4 Primary interviews 41
2.3.2 GROWTH FORECAST 41
2.4 DATA TRIANGULATION 42
2.5 MARKET SHARE ASSESSMENT 43
2.6 STUDY ASSUMPTIONS 43
2.7 GROWTH ASSUMPTIONS 43
2.8 RISK ASSESSMENT 45
2.9 RESEARCH LIMITATIONS 45
3 EXECUTIVE SUMMARY 46
4 PREMIUM INSIGHTS 51
4.1 PCR TECHNOLOGIES MARKET OVERVIEW 51
4.2 PCR TECHNOLOGIES MARKET, BY REGION, 2024 VS. 2030 (USD MILLION) 52
4.3 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY AND END USER,
2023 (USD MILLION) 53
4.4 PCR TECHNOLOGIES MARKET: GEOGRAPHIC SNAPSHOT 54
5 MARKET OVERVIEW 55
5.1 INTRODUCTION 55
5.2 MARKET DYNAMICS 55
5.2.1 DRIVERS 55
5.2.1.1 Increasing outbreaks of infectious diseases/viral persistence 55
5.2.1.2 Development of miniaturized and portable point-of-care testing devices 56
5.2.1.3 Integration of PCR technology with automation and data analysis tools 57
5.2.1.4 High demand for technologically advanced molecular diagnostics 58
5.2.2 RESTRAINTS 59
5.2.2.1 Premium product pricing 59
5.2.2.2 Dearth of skilled healthcare professionals 60
5.2.3 OPPORTUNITIES 61
5.2.3.1 Increased investments in laboratory infrastructure 61
5.2.3.2 Rising number of applications in rare sequence detection 61
5.2.4 CHALLENGES 62
5.2.4.1 Technical limitations 62
5.2.4.2 Increased pricing pressure on market players 62
5.3 VALUE CHAIN ANALYSIS 63
5.3.1 RESEARCH & DEVELOPMENT 63
5.3.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING 63
5.3.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES 63
5.4 PORTER’S FIVE FORCES ANALYSIS 65
5.4.1 THREAT OF NEW ENTRANTS 66
5.4.2 THREAT OF SUBSTITUTES 66
5.4.3 BARGAINING POWER OF SUPPLIERS 66
5.4.4 BARGAINING POWER OF BUYERS 66
5.4.5 INTENSITY OF COMPETITIVE RIVALRY 66
5.5 KEY STAKEHOLDERS AND BUYING CRITERIA 66
5.5.1 KEY STAKEHOLDERS IN BUYING PROCESS 67
5.5.2 KEY BUYING CRITERIA 67
5.6 PATENT ANALYSIS 68
5.6.1 LIST OF MAJOR PATENTS 69
5.7 KEY CONFERENCES AND EVENTS, 2024–2025 70
5.8 TRADE DATA ANALYSIS 71
5.8.1 IMPORT DATA FOR HS CODE 3822 71
5.8.2 EXPORT DATA FOR HS CODE 3822 72
5.9 PRICING ANALYSIS 72
5.9.1 PRICE TRENDS OF PCR TECHNOLOGIES, BY REGION 72
5.9.2 INDICATIVE SELLING PRICE OF PCR TECHNOLOGY PRODUCTS, BY REGION, 2021–2023 74
5.9.3 AVERAGE SELLING PRICE TREND, BY REGION 75
5.9.3.1 Average selling price trend of PCR technology equipment, by region 75
5.9.3.2 Average selling price trend of PCR instruments, by key player 76
5.10 UNMET NEEDS AND KEY PAIN POINTS 77
5.11 ECOSYSTEM ANALYSIS 77
5.12 SUPPLY CHAIN ANALYSIS 79
5.12.1 MANUFACTURING COMPANIES 79
5.12.2 SALES & DISTRIBUTION AGENTS 79
5.12.3 END USERS 79
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 80
5.14 TECHNOLOGY ANALYSIS 81
5.14.1 KEY TECHNOLOGIES 81
5.14.1.1 Thermal cyclers 81
5.14.1.2 Real-time quantitative PCR 81
5.14.1.3 Portable and point-of-care PCR 81
5.14.2 COMPLEMENTARY TECHNOLOGIES 82
5.14.2.1 Next-generation sequencing 82
5.14.2.2 Microarrays 82
5.14.2.3 Lab-on-a-chip devices 82
5.14.2.4 Robotics and automation 82
5.14.3 ADJACENT TECHNOLOGIES 83
5.14.3.1 Mass spectrometry 83
5.14.3.2 Single-cell sequencing 83
5.14.3.3 Fluorescence in situ hybridization 83
5.15 REGULATORY LANDSCAPE 83
5.15.1 REGULATORY ANALYSIS 84
5.15.1.1 North America 84
5.15.1.1.1 US 84
5.15.1.1.2 Canada 84
5.15.1.2 Europe 85
5.15.1.3 Asia Pacific 85
5.15.1.3.1 Japan 85
5.15.1.3.2 China 86
5.15.1.3.3 India 87
5.15.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
5.16 INVESTMENT AND FUNDING SCENARIO 89
5.17 REIMBURSEMENT SCENARIO ANALYSIS 90
5.18 IMPACT OF AI/GEN AI ON PCR TECHNOLOGIES MARKET 92
6 PCR TECHNOLOGIES MARKET, BY PRODUCT 94
6.1 INTRODUCTION 95
6.2 REAGENTS AND CONSUMABLES 95
6.2.1 INCREASING USE OF DPCR-BASED ANALYTICAL PROCEDURES IN GENETIC RESEARCH AND FORENSICS TO DRIVE MARKET 95
6.3 INSTRUMENTS 96
6.3.1 RISING AVAILABILITY OF TECHNOLOGICALLY ADVANCED AND INNOVATIVE PCR INSTRUMENTS TO FUEL MARKET GROWTH 96
6.4 SOFTWARE AND SERVICES 98
6.4.1 GROWING DEMAND FOR SPECIALIZED PCR ANALYSIS SOFTWARE FOR ONCOLOGY STUDIES AND FORENSICS TO SPUR MARKET GROWTH 98
7 PCR TECHNOLOGIES MARKET, BY TECHNIQUE 99
7.1 INTRODUCTION 100
7.2 REAL-TIME PCR 100
7.2.1 RISING ADOPTION OF REAL-TIME PCR AMONG RESEARCHERS AND HEALTHCARE PROFESSIONALS TO PROPEL MARKET GROWTH 100
7.3 CONVENTIONAL PCR 103
7.3.1 COST-EFFECTIVENESS AND EASE OF USAGE IN ROUTINE CLONING, GENOTYPING, AND MUTATION ANALYSIS TO FUEL MARKET GROWTH 103
7.4 DIGITAL PCR 106
7.4.1 FASTER RESULTS WITH LOWER MARGIN ERRORS TO DRIVE ADOPTION 106
7.5 REVERSE TRANSCRIPTION PCR 108
7.5.1 HIGHER SENSITIVITY FOR MEASURING CHANGES IN GENE EXPRESSION TO AUGMENT MARKET GROWTH 108
7.6 HOT-START PCR 111
7.6.1 BETTER REACTION SPECIFICITY WITH LOWER ERROR RATES TO FAVOR MARKET GROWTH 111
7.7 MULTIPLEX PCR 114
7.7.1 COST-EFFECTIVENESS AND HIGH THROUGHPUT TO AID MARKET GROWTH 114
7.8 OTHER PCR TECHNIQUES 117
 
8 PCR TECHNOLOGIES MARKET, BY APPLICATION 120
8.1 INTRODUCTION 121
8.2 DIAGNOSTIC APPLICATIONS 122
8.2.1 UNAVAILABILITY OF REIMBURSEMENTS FOR CLINICAL DIAGNOSTIC TESTS TO LIMIT MARKET GROWTH 122
8.3 GENOTYPING 123
8.3.1 LARGE TARGET PATIENT POPULATION FOR CANCER DIAGNOSIS TO AUGMENT MARKET GROWTH 123
8.4 NUCLEIC ACID DETECTION 124
8.4.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO BOOST MARKET GROWTH 124
8.5 GENE EXPRESSION ANALYSIS 125
8.5.1 INCREASED R&D FUNDING AND GRANTS FOR PCR TO FAVOR MARKET GROWTH 125
8.6 NUCLEIC ACID SYNTHESIS 126
8.6.1 INCREASED FOCUS ON PERSONALIZED AND PRECISE MEDICINES TO SUPPORT MARKET GROWTH 126
8.7 GENETIC SEQUENCING 127
8.7.1 TECHNOLOGICAL IMPROVEMENTS AND REDUCED COSTS OF SEQUENCING TO FUEL MARKET GROWTH 127
8.8 ENVIRONMENTAL APPLICATIONS 128
8.8.1 STRICT GOVERNMENT ENVIRONMENTAL POLICIES TO PROMOTE USE OF PCR 128
8.9 STANDARD VALIDATION/VERIFICATION 129
8.9.1 NEED FOR REGIONAL/GLOBAL VALIDATION FOR COMMERCIAL/NON-COMMERCIAL GUIDELINE FRAMING TO DRIVE MARKET 129
8.10 OTHER APPLICATIONS 129
9 PCR TECHNOLOGIES MARKET, BY END USER 131
9.1 INTRODUCTION 132
9.2 HOSPITAL LABORATORIES 132
9.2.1 RISING PUBLIC AWARENESS OF ROUTINE CHECKUPS TO SUPPORT MARKET GROWTH 132
9.3 DIAGNOSTIC LABORATORIES 133
9.3.1 ESTABLISHMENT OF INDEPENDENT SPECIALIZED DIAGNOSTIC LABORATORIES TO PROPEL MARKET GROWTH 133
9.4 ACADEMIC AND GOVERNMENT ORGANIZATIONS 134
9.4.1 INCREASED GOVERNMENT SUPPORT FOR GENOME-BASED RESEARCH TO DRIVE MARKET 134
9.5 PHARMA-BIOTECH COMPANIES 135
9.5.1 INCREASING R&D INITIATIVES BY PHARMA-BIOTECH COMPANIES TO DRIVE ADOPTION OF PCR TECHNOLOGIES 135
9.6 OTHER END USERS 136
 
10 PCR TECHNOLOGIES MARKET, BY REGION 138
10.1 INTRODUCTION 139
10.2 NORTH AMERICA 139
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 140
10.2.2 US 145
10.2.2.1 US to dominate North American PCR technologies market during study period 145
10.2.3 CANADA 147
10.2.3.1 Supportive government initiatives for genomics research to aid market growth 147
10.3 EUROPE 149
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 149
10.3.2 GERMANY 153
10.3.2.1 Presence of well-established pharmaceutical and R&D industry to augment market growth 153
10.3.3 FRANCE 155
10.3.3.1 Increasing investments in life science R&D for infrastructural development to favor market growth 155
10.3.4 UK 157
10.3.4.1 Rising acceptance of genome-based diagnosis by clinicians and healthcare professionals to spur market growth 157
10.3.5 ITALY 159
10.3.5.1 Supportive government policies and high healthcare expenditure to boost market growth 159
10.3.6 SPAIN 161
10.3.6.1 Increasing funding for life science research and pharmaceutical drug development to boost market growth 161
10.3.7 REST OF EUROPE 162
10.4 ASIA PACIFIC 164
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 164
10.4.2 CHINA 169
10.4.2.1 Improved public access to modern healthcare facilities and advanced genomics research to fuel market growth 169
10.4.3 JAPAN 170
10.4.3.1 Well-established healthcare infrastructure and advanced cancer research activities to support market growth 170
10.4.4 INDIA 172
10.4.4.1 Presence of large target patient population and high government healthcare expenditure to support market growth 172
10.4.5 AUSTRALIA 174
10.4.5.1 High healthcare expenditure to drive adoption of advanced PCR technologies 174
10.4.6 SOUTH KOREA 176
10.4.6.1 Improved medical tourism and prevalence of chronic diseases to propel market growth 176
10.4.7 REST OF ASIA PACIFIC 178
10.5 LATIN AMERICA 179
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 179
10.5.2 BRAZIL 183
10.5.2.1 Growing focus on proteomics and genomics research to drive market 183
10.5.3 MEXICO 185
10.5.3.1 Favorable trade agreements to support imports and improve accessibility to PCR instruments 185
10.5.4 REST OF LATIN AMERICA 187
10.6 MIDDLE EAST & AFRICA 188
10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 189
10.6.2 GCC COUNTRIES 192
10.6.2.1 Advancements in healthcare infrastructure and increased focus on personalized medicines to fuel market growth 192
10.6.3 REST OF MIDDLE EAST & AFRICA 193
11 COMPETITIVE LANDSCAPE 195
11.1 INTRODUCTION 195
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN 195
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PCR TECHNOLOGIES MARKET 195
11.3 REVENUE ANALYSIS, 2019–2023 197
11.4 MARKET SHARE ANALYSIS, 2023 197
11.4.1 GLOBAL PCR INSTRUMENTS MARKET SHARE, BY KEY PLAYER, 2023 197
11.4.2 GLOBAL PCR REAGENTS AND CONSUMABLES MARKET SHARE, BY KEY PLAYER, 2023 198
11.4.3 GLOBAL PCR SOFTWARE AND SERVICES MARKET SHARE, BY KEY PLAYER, 2023 199
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 201
11.5.1 STARS 201
11.5.2 EMERGING LEADERS 201
11.5.3 PERVASIVE PLAYERS 201
11.5.4 PARTICIPANTS 202
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 203
11.5.5.1 Company footprint 203
11.5.5.2 Product footprint 204
11.5.5.3 Application footprint 204
11.5.5.4 Technique footprint 205
11.5.5.5 End-user footprint 206
11.5.5.6 Region footprint 207
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 207
11.6.1 PROGRESSIVE COMPANIES 207
11.6.2 RESPONSIVE COMPANIES 208
11.6.3 DYNAMIC COMPANIES 208
11.6.4 STARTING BLOCKS 208
11.6.5 COMPANY BENCHMARKING: STARTUPS/SMES, 2023 209
11.7 COMPANY VALUATION AND FINANCIAL METRICS 210
11.8 PRODUCT/BRAND COMPARISON 212
11.9 COMPETITIVE SCENARIO 212
11.9.1 PRODUCT LAUNCHES AND APPROVALS 213
11.9.2 DEALS 213
12 COMPANY PROFILES 215
12.1 KEY PLAYERS 215
12.1.1 THERMO FISHER SCIENTIFIC INC. 215
12.1.1.1 Business overview 215
12.1.1.2 Products/Services/Solutions offered 216
12.1.1.3 Recent developments 218
12.1.1.3.1 Product launches and approvals 218
12.1.1.3.2 Deals 219
12.1.1.4 MnM view 220
12.1.1.4.1 Key strengths 220
12.1.1.4.2 Strategic choices 220
12.1.1.4.3 Weaknesses and competitive threats 220
12.1.2 F. HOFFMANN-LA ROCHE LTD. 221
12.1.2.1 Business overview 221
12.1.2.2 Products/Services/Solutions offered 222
12.1.2.3 Recent developments 224
12.1.2.3.1 Product launches and approvals 224
12.1.2.3.2 Deals 225
12.1.2.4 MnM view 225
12.1.2.4.1 Key strengths 225
12.1.2.4.2 Strategic choices 225
12.1.2.4.3 Weaknesses and competitive threats 225
12.1.3 AGILENT TECHNOLOGIES, INC. 226
12.1.3.1 Business overview 226
12.1.3.2 Products/Services/Solutions offered 227
12.1.3.3 Recent developments 230
12.1.3.3.1 Product launches 230
12.1.3.3.2 Deals 230
12.1.3.4 MnM view 230
12.1.3.4.1 Key strengths 230
12.1.3.4.2 Strategic choices 230
12.1.3.4.3 Weaknesses and competitive threats 231
 
12.1.4 BIO-RAD LABORATORIES, INC. 232
12.1.4.1 Business overview 232
12.1.4.2 Products/Services/Solutions offered 233
12.1.4.3 Recent developments 236
12.1.4.3.1 Product launches 236
12.1.4.3.2 Deals 236
12.1.4.4 MnM view 237
12.1.4.4.1 Key strengths 237
12.1.4.4.2 Strategic choices 237
12.1.4.4.3 Weaknesses and competitive threats 237
12.1.5 QIAGEN 238
12.1.5.1 Business overview 238
12.1.5.2 Products/Services/Solutions offered 239
12.1.5.3 Recent developments 241
12.1.5.3.1 Product launches and approvals 241
12.1.5.3.2 Deals 242
12.1.5.4 MnM view 243
12.1.5.4.1 Key strengths 243
12.1.5.4.2 Strategic choices 243
12.1.5.4.3 Weaknesses and competitive threats 243
12.1.6 DANAHER CORPORATION 244
12.1.6.1 Business overview 244
12.1.6.2 Products/Services/Solutions offered 245
12.1.6.3 Recent developments 247
12.1.6.3.1 Product approvals 247
12.1.6.3.2 Deals 247
12.1.7 ABBOTT 248
12.1.7.1 Business overview 248
12.1.7.2 Products/Services/Solutions offered 249
12.1.7.3 Recent developments 250
12.1.7.3.1 Product approvals 250
12.1.8 TAKARA BIO INC. 251
12.1.8.1 Business overview 251
12.1.8.2 Products/Services/Solutions offered 252
12.1.8.3 Recent developments 254
12.1.8.3.1 Deals 254
12.1.9 ANALYTIK JENA GMBH+CO. KG 255
12.1.9.1 Business overview 255
12.1.9.2 Products/Services/Solutions offered 255
12.1.9.3 Recent developments 256
12.1.9.3.1 Product launches 256
12.1.9.3.2 Deals 257
12.1.10 MERCK KGAA 258
12.1.10.1 Business overview 258
12.1.10.2 Products/Services/Solutions offered 259
12.1.11 BIONEER CORPORATION 263
12.1.11.1 Business overview 263
12.1.11.2 Products/Services/Solutions offered 264
12.1.12 PERKINELMER 266
12.1.12.1 Business overview 266
12.1.12.2 Products/Services/Solutions offered 267
12.1.12.3 Recent developments 268
12.1.12.3.1 Other developments 268
12.1.13 BECTON, DICKINSON AND COMPANY 269
12.1.13.1 Business overview 269
12.1.13.2 Products/Services/Solutions offered 270
12.1.13.3 Recent developments 271
12.1.13.3.1 Product launches and approvals 271
12.1.13.3.2 Deals 272
12.1.14 STANDARD BIOTOOLS 273
12.1.14.1 Business overview 273
12.1.14.2 Products/Services/Solutions offered 274
12.1.15 HOLOGIC, INC. 276
12.1.15.1 Business overview 276
12.1.15.2 Products/Services/Solutions offered 277
12.1.15.3 Recent developments 278
12.1.15.3.1 Product launches 278
12.1.16 LONZA 279
12.1.16.1 Business overview 279
12.1.16.2 Products/Services/Solutions offered 280
12.1.17 ILLUMINA, INC. 281
12.1.17.1 Business overview 281
12.1.17.2 Products/Services/Solutions offered 282
12.1.18 SANSURE BIOTECH INC. 283
12.1.18.1 Business overview 283
12.1.18.2 Products/Services/Solutions offered 284
12.2 OTHER PLAYERS 285
12.2.1 PROMEGA CORPORATION 285
12.2.2 LIMING BIO 286
12.2.3 EPPENDORF SE 287
12.2.4 TRANSGEN BIOTECH CO., LTD. 288
12.2.5 DAAN GENE CO., LTD. 289
12.2.6 BIOBASE GROUP 290
12.2.7 NIPPON GENETICS EUROPE 291
12.2.8 BIOMÉRIEUX 292
12.2.9 DAIICHI SANKYO COMPANY, LIMITED 293
12.2.10 STILLA 294
12.2.11 GENSCRIPT 295
13 APPENDIX 296
13.1 DISCUSSION GUIDE 296
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 301
13.3 CUSTOMIZATION OPTIONS 303
13.4 RELATED REPORTS 303
13.5 AUTHOR DETAILS 304